The People vs. AbbVie
Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...
Thanks to the European Commission, Biogen can extend Tecfidera monopoly for at least two...
According to an investigation by Follow the Money, a Dutch investigative journalism outlet, the European Commission restored the market exclusivity of Tecfidera, a multiple...
Commission report on competition enforcement in the pharmaceutical sector
Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...
Wrapping up 2022 with some noteworthy medicines, law and policy events
Welcome to our annual, highly biased, overview of noteworthy events in the field of medicines law and policy.
Also in 2022, Covid-19 remained a central...
The elephant in the room at the WHO Executive Board
The World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus spoke harshly about the lack of Covid-19 vaccines in developing countries at the opening of...
World Health Organization Members ask for more time to solve difficult negotiations on access...
World Health Organization member states will propose to continue negotiations on a critical annex to the Pandemic Agreement, after being unable to bridge key...
MSF’s Access Campaign is an invaluable actor in global health; shutting it down is...
On 20 June, STAT News reported that Médecins Sans Frontières (MSF) is closing down their Access Campaign, effective as of 31 December 2024. It...
High medicines prices in Europe – do not Brexit the people
The issues of high priced medicines and problems with access to medicines have for many years been themes belonging to the realm of global...
Wrapping up 2020 with some noteworthy medicines, law and policy events
Wrapping up the year 2020 can’t happen soon enough. This year, one way or the other, most people on the planet have been affected...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...